kind glp-1 patches Companion System GLP-1 meds changed the game

Getting started early also makes it easier to gather medical records and other evidence while theyre still accessible

Most patients experience blood pressure reduction or stability on GLP-1 medications

Wu L, Xia M, Duan Y, Zhang L, Jiang H, Hu X, et al

Convenience matters, but people still expect strong clinical results from oral GLP-1s

This surge in obesity rates is closely linked to a heightened risk of chronic diseases such as type 2 diabetes, cardiovascular diseases, and certain cancers

The first generation of GLP-1 therapies exhibit reduced susceptibility to enzymatic degradation, while providing effective glucose control, improved -cell function, body weight loss and decreased systolic blood pressure in patients with T2D (Meier, 2012) The newly developed incretin mimetics, including albiglutide, dulaglutide and semaglutide, are designed to have extended pharmacokinetic profiles and efficacy suitable once-weekly administration